CN Bio hires Director of Licensing

CN Bio Innovations (CN Bio) announced today the appointment of Gavin Clark to the role of Director of Licensing. This is a new position created to facilitate the commercialization of CN Bio’s novel proprietary infectious disease models. Gavin brings with him over 35 years of experience in the pharmaceutical industry including roles as Global Licensing… Read more »


Liver disease to become a bigger killer than heart disease or cancer

Liver disease has the potential to become the UK’s biggest killer within a generation, is the stark assessment of an independent report released today by a group of politicians and liver experts. The damning report highlights the “scandalous” absence of a national strategy to tackle liver disease, the result of which is a “shameful waste of… Read more »


Zyoxel Ltd to become CN Bio Innovations Ltd

Zyoxel, an expert in advanced in vitro 3D liver models for drug discovery and drug testing, has today announced it is changing its name to CN Bio Innovations Ltd  (CNBIO). The move is part of a strategic rebrand designed to closer align the organisation with its Hong Kong-based holding company, CN Innovations Holdings Limited (CNI)…. Read more »